请选择 进入手机版 | 继续访问电脑版
查看: 308|回复: 0

HMS-CSSA 第二届华人创业论坛路演项目征集暨嘉宾简介

[复制链接]

参加活动: 0

组织活动: 308

322

主题

322

帖子

1381

积分

金牌会员

Rank: 6Rank: 6

积分
1381
发表于 2017-4-6 01:01:57 | 显示全部楼层 |阅读模式
活动类型:
讲座
活动时间:
2017-4-30 09:00 AM 至 2017-4-30 02:00 PM 商定
活动地点:
哈佛医学院
已报名人数:
0

活动评分

0

 

0(投票)

  •     5分 0.0%
  •     4分 0.0%
  •     3分 0.0%
  •     2分 0.0%
  •     1分 0.0%

  • 活动查看
  • 活动相册
  • 已通过
微信图片_20170406135610.jpg
医学院各位在创业路上的小伙伴们!
我们 HMS-CSSA 即将举办第二届创业论坛!
现诚邀感兴趣的朋友前来参加,机会不容错过!



活动介绍

随着新英格兰地区华人专家学者群体中创业的人数激增,哈佛医学院HMS-CSSA希望通过举办创业论坛和项目路演的形式为正在创业或者有创业打算的群体提供一个能够交流、学习和帮助的平台。此次论坛的目的在于为我们医学院的创业者提供一个与众多天使投资人深度接触的机会,并通过多方参与研讨,帮助创业者分析项目商业模式的可行性、评估项目的价值和制定最佳发展路线!

本次活动将评选出优秀路演项目,并给予奖励。

一等奖一名:奖金+证书
二等奖一名:证书

时间
04/30/2017 (星期日)

活动安排


9:00am-9:30am:
Alan Jiang, PhD, CSO, XtalPi

9:30am-10:00am:
Xiaoyu Tian, PhD, Vice President of Product Development, VcanBio

10:00am-10:30am:
Topic: Intellectual Property Protection in USA
(Taking example of the gene editing Crispr/Cas9 patent)
Jeff Clark, J.D. & M.D.  Associate at DLA Piper

10:30am-11:00am:
Chesley Chen, CEO, Saftypartners, USA
Topic: Zen and the Art of CEO Maintenance

11:00am-13:00pm:
项目路演及评奖

13:00 pm-14:00 pm:
午餐和自由交流


目前确认受邀嘉宾包括: Yongjin Group (涌金集团); Legend Capital (君联资本);CSC Group (中科招商);Wuxi Healthcare Venture (毓承资本) 等等


感兴趣的同学请于4月21号前将创业项目简介(300-500字,或slides)发送至[url=]CSSA@HMS-CSSA.ORG[/url]
[url=][/url]



嘉宾简介

Jeff Clark, J.D, M.D.

微信图片_20170406135633.jpg

(Jeff is also among those drafted the ground breaking CRISPR/Cas9 gene editing patent.)

Jeff Clark, M.D., J.D. is an associate at DLA Piper with a focus on patent litigation and the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multi-district product liability litigation. Jeff also concentrates his practice on all aspects of patent law including patent prosecution and strategic counseling for life science start-ups, biotech, medical device and pharmaceutical companies. Jeff has extensive clinical and basic science research experience. He was a clinical research fellow in the Molecular and Vascular Medicine Unit, Renal Division (Department of Medicine), at Beth Israel Deaconess Medical Center and in the Cardiovascular Research Center (Department of Cardiology) at Massachusetts General Hospital. Jeff has authored and co-authored several publications in peer-reviewed journals and has presented at the national American Society of Nephrology Renal Week conference.


Chesley Chen, CEO, Saftypartners, USA
微信图片_20170406140034.jpg
As Chief Executive Officer, Chesley oversees Safety Partners’ operations and strategic planning, including administration, marketing, and service delivery. Chesley brings over three decades of business-building experience across various industries and organizations, and a unique blend of corporate financial management, client relationship building, and executive leadership skill. Chesley joined Safety Partners from Good Measures LLC where he was Executive Vice President and where he currently serves as a Board Advisor. Prior to working with Good Measures LLC he was the Chief Executive Officer of the Warner Babcock Institute for Green Chemistry LLC, and Vice President of Client Services and Product Development for Health Dialog Corporation. Chesley holds a Bachelor of Science in Civil Engineering from Tufts University, a Master of Science in Aeronautics and Astronautics from MIT, and a Master of Business Administration from Harvard Business School. He is an Industry Advisor at the Tufts Gordon Institute.


Alan Jiang, PhD, CSO, XtalPi
微信图片_20170406140126.jpg
Yide Alan Jiang oversees global market positioning and strategy development at XtalPi. Dr.Jiang has 14 years of experience in biopharmaceutical R&D, with expertise in managing external translational science collaborations between academia, industry and contract research organizations. Prior to joining XtalPi, Dr. Jiang held the role of Director of Asia R&D strategy and Associate Scientific Director at Genzyme, where he led cross-functional R&D collaborations and projects in Asia and conducted external consultation for various companies on R&D strategy and processes. His completed his postdoctoral fellowship of hematology and oncology at Harvard Medical School, and has worked as project manager at China’s National Institute for the Control of Pharmaceutical and Biological Products (NICPBP, NIFDC), CFDA.

Dr. Jiang earned his Ph.D. in molecular biology from University of Tennessee-Health Science Center and M.D. from Shanghai Medical University (now Shanghai Medical College of Fudan University).

(叶琼)

主办:

哈佛医学院华人专家学者联合会(HMS-CSSA


协办:

纽英伦中华咨询网络协会(NECINA

美中生物医药协会(CABA

美中医药开发协会(SAPA


微信图片_20170406135715.jpg
微信图片_20170406140203.png

微信图片_20170406140214.png

微信图片_20170406140227.png



哈佛大学医学院华人专家学者联合会
website: http://www.hms-cssa.org
微信公众号: hmscssa


焦点图显示:

到期时间:
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

推荐阅读 More>
广告位

Powered by Boston Web Power
技术支持:Boston Web Power

© 2008-2016 波士顿万家网

合作伙伴

返回顶部 返回列表